SPMS

News

Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.

News

Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.